Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Curie-Cancer Trebles Early Phase Clinical Research Studies with Industry Partners

Published: Tuesday, March 26, 2013
Last Updated: Tuesday, March 26, 2013
Bookmark and Share
Ten early stage clinical studies (phase I) were conducted in 2012, trebling since 2010 and continuing to grow in 2013.

Curie-Cancer has announced a strong increase in the number of early stage clinical trials (phase I) from three in 2010 to ten in 2012. The studies are being conducted with industry partners.

The rise in the number of studies is a direct result of the changes in strategic direction put in place by professor Pierre Teillac, director of the Institut Curie Hospital Group and the recent launch of the Clinical Research Department, headed by Veronique Dieras, in response to the needs of industry partners.

These studies aim to evaluate a compound’s safety and pharmacokinetics (absorption rate, elimination rate, maximum blood concentration, etc.) in patients to establish the subsequent dosage of the drug.

The studies also research the first signs of efficacy. These studies are becoming increasingly crucial to the pharmaceutical companies, who seek experienced investigation that is reliable, efficient and reduces turnaround.

“The 2012 increase in early stage clinical trials for Curie-Cancer is rather remarkable. Due to contracts signed at the start of 2013, we expect the number to continue to climb significantly,” said Christophe Le Tourneau, the oncologist responsible for the Institut Curie’s early stage clinical studies.

Tourneau continued, “We have many diverse industry partners working on studies of different types of cancer. They range from French SMEs to international groups.”

Dr Patricia Tresca, who has extensive experience within the pharmaceutical industry, now leads the body in charge of managing clinical trials for Curie-Cancer.

She was recruited for her working knowledge of the industry partner types Curie-Cancer targets. Curie-cancer has been tasked with improving responsiveness and inclusion rates in patients.

It will help industry partners to obtain the reports they need in time to make their decisions faster. Industry partners will also be able to request the necessary authorizations from the monitoring authorities in order to proceed to the next development stages.

Curie-Cancer’s main advantage is achieving the close collaboration between research doctors, who are conducting the trials and the researchers in charge of translational and/or fundamental research.

In the age of genomics and proteomics, preliminary studies are often best conducted at the cutting edge of academic research. As researchers are involved in conducting the preclinical studies, they are in a position to best interpret the results.

They can therefore make the right decisions quickly. An increasing number of the products studied in “first in man“ trials at the Institut Curie have also been studied previously in preclinical studies commissioned by industry partners with different research laboratories on campus.

Another advantage is Curie-Cancer’s ability to conduct early stage clinical studies for industry partners accustomed to commissioning preclinical studies with them.

They know that the partnership will bring benefits from conducting further clinical studies of their products in development.

The opportunity for researchers to participate in these early stage studies, upon which the future of many products is decided, is very interesting. It allows them to link concepts derived in a laboratory, through in vitro or animal test results, to the first observations in patients.

“Clinical research has meaning only if it makes innovative products available to patients. Allowing early stage access to these products in development within pharmaceutical laboratories is an additional opportunity for those whose commercially available products are not efficient enough,” said Damien Salauze, director of Curie-Cancer.

Salauze continued, “We are pleased that the expertise and knowledge that Curie-Cancer brings to our industry partners can be combined with added hope for patients.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Curie-Cancer and Strand Launch Curie Image Database
A breakthrough image management platform for scientists.
Wednesday, December 18, 2013
Curie-Cancer and Meiogenix Sign Two Partnership Agreements
Curie-Cancer and Meiogenix will develop the SpiX technology in yeast and in mice to unlock unexplored genetic diversity.
Tuesday, November 19, 2013
Curie-Cancer and Harmonic Pharma Sign a Partnership Agreement
Under this multi-year research collaboration, Curie-Cancer will give Harmonic Pharma access to its extensive collection of patient-derived xenografts representative of human tumors.
Tuesday, November 06, 2012
Scientific News
Sorting Through Cellular Statistics
Aaron Dinner, professor in chemistry, and his graduate student Herman Gudjonson are trying to read the manual of life, DNA, as part of the Dinner group’s research into bioinformatics—the application of statistics to biological research.
Playing 'Tag' with Pollution lets Scientists See Who's It
Using a climate model that can tag sources of soot from different global regions and can track where it lands on the Tibetan Plateau, researchers have determined which areas around the plateau contribute the most soot — and where.
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
High-Resolution 3D Images Reveal the Muscle Mitochondrial Power Grid
NIH mouse study overturns scientific ideas on energy distribution in muscle.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
Paving the way to Better Ovarian Cancer Diagnosis
Aïcha BenTaieb will present her invention for automated identification of ovarian cancer’s many subtypes at an international conference this fall.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!